Table 1 The demographic, clinical, and laboratory data of the study group of 103 SLE patients
Items | N = 103 (100%) |
|---|---|
Demographic data | |
 Age mean ± SD (range, 12‑45) | 29.2 ± 7.4 |
 Sex, no. (%) | |
  Female | 91 (87.35%) |
  Male | 12 (11.65%) |
 Smoking, no. (%) | |
  Smoker | 7 (6.8%) |
  Non-smoker | 96 (93.2) |
 Disease duration (years) | 4‑10 months |
 Mean ± SD | 4 ± 2 |
Clinical features | |
 Malar rash, no. (%) | 35 (34.0%) |
 Photosensitivity, no. (%) | 34 (33.0%) |
 Oral ulcer, no. (%) | 21 (20.4%) |
 Arthritis, no. (%) | 30 (29.1%) |
 Pleurisy | 22 (21.4%) |
 Pericarditis | 21 (20.4%) |
 Proteinuria more than 0.5 g | 65 (63.1%) |
 Vasculitis | 12 (11.7%) |
 Fever > 38 | 17 (16.5%) |
 Seizure | 11 (10.7%) |
 Psychosis | 7 (6.8%) |
 Lupus headache | 15 (14.6%) |
 CVA | 13 (12.6%) |
 SLEDAI, mean ± SD (2‑48) | 18 ± 10 |
 SLICC, mean ± SD (0‑15) | 5 ± 3 |
 APACHE II score, mean ± SD (7‑39) | 19 ± 8 |
Laboratory investigations | |
 Hemolytic anemia | 18 (17.5%) |
 Leukopenia less 4000 | 22 (21.4%) |
 Lymphopenia less 1500 | 26 (25.2%) |
 Thrombocytopenia | 31 (30.1%) |
 ANA | 76 (73.8%) |
 Anti-dsDNA | 74 (71.8%) |
 HypoC3 | 37 (35.9%) |
 HypoC4 | 37 (35.9%) |
Medications | |
 Steroid | 73 (70.9%) |
 Azathioprine | 53 (51.5%) |
 Cyclophosphamide | 22 (21.4%) |
 Chloroquine | 81 (78.6%) |
 Mycophenolate mofetil | 20 (19.4%) |
 Cyclosporine | 5 (4.9%) |
 Combined therapy | 93 (90.2%) |
Total SLE patients | 103 (100%) |
 No admission to ICU | 81 (78.6%) |
 Admitted to ICU | 22 (21.4%) |
 Died | 4 (18.2%) |
 Survival | 18 (81.8%) |